EA201201222A1 - SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS) - Google Patents

SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)

Info

Publication number
EA201201222A1
EA201201222A1 EA201201222A EA201201222A EA201201222A1 EA 201201222 A1 EA201201222 A1 EA 201201222A1 EA 201201222 A EA201201222 A EA 201201222A EA 201201222 A EA201201222 A EA 201201222A EA 201201222 A1 EA201201222 A1 EA 201201222A1
Authority
EA
Eurasian Patent Office
Prior art keywords
solid dosage
action
possessing
options
solid medicine
Prior art date
Application number
EA201201222A
Other languages
Russian (ru)
Other versions
EA020061B1 (en
Inventor
Анастасия Геннадьевна ЧЕЛЯЕВА
Владимир Павлович ЛОБКО
Олег Олегович ТИХОНЕНКО
Original Assignee
Анастасия Геннадьевна ЧЕЛЯЕВА
Владимир Павлович ЛОБКО
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Анастасия Геннадьевна ЧЕЛЯЕВА, Владимир Павлович ЛОБКО filed Critical Анастасия Геннадьевна ЧЕЛЯЕВА
Priority to EA201201222A priority Critical patent/EA020061B1/en
Publication of EA201201222A1 publication Critical patent/EA201201222A1/en
Publication of EA020061B1 publication Critical patent/EA020061B1/en

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к области фармацевтической промышленности и медицине и может быть использовано при создании и применении твердых лекарственных форм для лечения и/или профилактики ожирения. Задачей настоящего изобретения является создание эффективной твердой лекарственной формы с использованием сибутрамина гидрохлорида моногидрата, обладающей анорексигенным действием. Задача решается за счет введения в состав твердой лекарственной формы дополнительных минеральных веществ, а также за счет использования изотопов углеродаС и азотаN. Техническими результатами изобретения являются увеличение лечебного эффекта (снижение веса тела или уменьшение скорости прироста веса тела) при сохранении продолжительности действия без увеличения концентрации сибутрамина гидрохлорида моногидрата при лечении и/или профилактики ожирения; сокращение времени наступления лечебного эффекта.The invention relates to the pharmaceutical industry and medicine and can be used in the creation and use of solid dosage forms for the treatment and / or prevention of obesity. The present invention is the creation of an effective solid dosage form using sibutramine hydrochloride monohydrate with anorexigenic action. The problem is solved by introducing into the solid dosage form additional minerals, as well as through the use of carbon isotopes and nitrogen. The technical results of the invention are to increase the therapeutic effect (decrease in body weight or decrease in the rate of weight gain) while maintaining the duration of action without increasing the concentration of sibutramine hydrochloride monohydrate in the treatment and / or prevention of obesity; reducing the time of onset of therapeutic effect.

EA201201222A 2012-10-02 2012-10-02 Solid dosage form having an anorectic effect (variants) EA020061B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EA201201222A EA020061B1 (en) 2012-10-02 2012-10-02 Solid dosage form having an anorectic effect (variants)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EA201201222A EA020061B1 (en) 2012-10-02 2012-10-02 Solid dosage form having an anorectic effect (variants)

Publications (2)

Publication Number Publication Date
EA201201222A1 true EA201201222A1 (en) 2013-04-30
EA020061B1 EA020061B1 (en) 2014-08-29

Family

ID=48183086

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201222A EA020061B1 (en) 2012-10-02 2012-10-02 Solid dosage form having an anorectic effect (variants)

Country Status (1)

Country Link
EA (1) EA020061B1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PA8591801A1 (en) * 2002-12-31 2004-07-26 Pfizer Prod Inc BENZAMID INHIBITORS OF THE P2X7 RECEIVER.
RU2426443C2 (en) * 2007-02-23 2011-08-20 Хилл'С Пет Ньютришн, Инк. Compositions and methods for animal weight control (versions)

Also Published As

Publication number Publication date
EA020061B1 (en) 2014-08-29

Similar Documents

Publication Publication Date Title
MX2016005532A (en) Methods for using nitric oxide in a plasma state to treat medical conditions and diseases.
EA201790195A1 (en) METHODS OF TREATING CANCER WITH THE USE OF TIGIT INHIBITORS AND ANTI-CANCER AGENTS
MX2022013172A (en) Use of a pcsk9 inhibitor to treat hyperlipidemia.
MX2022003072A (en) Use of pridopidine for treating functional decline.
MX2019006900A (en) Methods of therapeutic monitoring of nitrogen scavenging drugs.
EA201490378A1 (en) TREATMENT OF MULTIPLE SCLEROSIS USING THE COMBINATION OF LACHINIMODA AND INTERFERON-β
EA201391286A1 (en) TREATMENT OF SOLID TUMORS
PH12018501443A1 (en) Methods of administering hepcidin
NZ702730A (en) Treatment of motor and movement disorder side effects associated with parkinson’s disease treatments
MX2018010223A (en) Combination therapy for treatment of ovarian cancer.
PH12016501554A1 (en) Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, method for screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and method for monitoring sensitivity of anticancer drug
EA201490045A1 (en) DEUTERED 1-PIPERAZINO-3-PHENYLINDANES USED TO TREAT SCHIZOPHRENIA
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
NZ754328A (en) Marker for acid sphingomyelinase disorders and uses thereof
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
PH12019501358A1 (en) Methods of administering hepcidin
EA201201222A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
EA201201209A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
EA201201224A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
EA201201223A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
EA201201225A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
EA201201210A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
EA201201211A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
EA201201207A1 (en) SOLID MEDICINE FORM, possessing an anorexigenic action (OPTIONS)
GB201115977D0 (en) Neurodevelopmental disorders

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU

NF4A Restoration of lapsed right to a eurasian patent

Designated state(s): RU

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU